Treat to Target in Inflammatory Bowel Disease

Inflammatory Bowel Disease (G Lichtenstein, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease

Opinion statement

With the expanding armamentarium in IBD the current treatment targets can be reached. By optimally using our drugs we can avoid long-term complications in IBD. For this the therapeutic strategy has to be changed from a clinically driven approach to a target-driven strategy. Currently mucosal healing, normalization of biomarkers, histological healing, and healing on abdominal imaging are proposed targets. Correct phenotyping of the patient before initiation of therapy is mandatory. Once treatment is initiated a continuous re-evaluation with consequent adaptation of the treatment when goals are not (yet) reached is needed. Both escalation and de-escalation should be considered. Drug levels can be used as a guidance to reach these targets.


Treat to target Mucosal healing Biomarkers MRE Histological healing IBD 


Compliance with Ethical Standards

Conflict of Interest

Peter Bossuyt reports grants from Abbvie, consultancy or speakers fees from Mundipharma, MSD, Robarts, and Hospira, outside the submitted work.

Séverine Vermeire reports grants from Abbvie, Takeda, MSD, and consultancy or speakers fees paid to the institution from Abbvie, Takeda, MSD, Pfizer, Genentech/Roche, Galapagos, Hospira, Mundipharma, J&J, Shire, Ferring, and Cellgene.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-Biroulet L, et al. Clinical trials in ulcerative colitis: a historical perspective. J Crohns Colitis. 2015.Google Scholar
  2. 2.
    Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-Biroulet L, et al. Clinical trials in luminal Crohn’s disease: a historical perspective. J Crohns Colitis. 2014;8(11):1339–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Castrejón I, Pincus T. Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes—consequences for clinical care. Bull NYU Hosp Jt Dis. 2011;69(2):104–10.PubMedGoogle Scholar
  4. 4.
    Doria A, Gatto M, Iaccarino L, Punzi L. Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. Lupus. 2015;24(4–5):507–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Wendling D. Treating to target in axial spondyloarthritis: defining the target and the arrow. Expert Rev Clin Immunol. 2015;11(6):691–3.CrossRefPubMedGoogle Scholar
  6. 6.
    Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2015.Google Scholar
  7. 7.••
    Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015. This article reviews the current evidence for a workable treat-to-target strategy in rheumatoid arthritis. These recommendations are the framework for further clinical trial of a treat to target strategy in IBD.Google Scholar
  8. 8.
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):65–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res. 2013;65(9):1401–9.CrossRefGoogle Scholar
  11. 11.
    Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch rheumatoid arthritis monitoring registry. Ann Rheum Dis. 2012;71(6):845–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis. 2011;70(4):611–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    van Eijk IC, Nielen MM, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BA, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford). 2012;51(4):686–94.CrossRefGoogle Scholar
  14. 14.
    Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord. 2013;14:350.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37.CrossRefPubMedGoogle Scholar
  16. 16.
    Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63(1):88–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015.Google Scholar
  18. 18.
    Frøslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–22.CrossRefPubMedGoogle Scholar
  19. 19.
    Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15(9):1295–301.CrossRefPubMedGoogle Scholar
  20. 20.
    Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8. quiz e10-1.CrossRefPubMedGoogle Scholar
  21. 21.
    D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2(3):219–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–201.CrossRefPubMedGoogle Scholar
  24. 24.
    Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol. 2014;20(17):4980–6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bessissow T, Van Keerberghen CA, Van Oudenhove L, Ferrante M, Vermeire S, Rutgeerts P, et al. Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. J Crohns Colitis. 2013;7(11):e580–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Rubin DT, Cleveland NK. Using a treat-to-target management strategy to improve the doctor-patient relationship in inflammatory bowel disease. Am J Gastroenterol. 2015;110(9):1252–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol. 2015.Google Scholar
  30. 30.
    Sandborn WJ, Panes J, Zhang H, Yu D, Niezychowski W, Su C. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology. 2015.Google Scholar
  31. 31.
    D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, et al. Faecal calprotectin assay after induction with anti-tumour necrosis factor alpha agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig Liver Dis. 2014;46(11):974–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Molander P, af Bjorkesten CG, Mustonen H, Haapamaki J, Vauhkonen M, Kolho KL, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis. 2012;18(11):2011–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Guardiola J, Lobaton T, Rodriguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12(11):1865–70.CrossRefPubMedGoogle Scholar
  35. 35.
    Labaere D, Smismans A, Van Olmen A, Christiaens P, D’Haens G, Moons V, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. U Eur Gastroenterol J. 2014;2(1):30–7.CrossRefGoogle Scholar
  36. 36.
    Calafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21(5):1072–6.CrossRefPubMedGoogle Scholar
  37. 37.
    De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19(10):2111–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol. 2015;110(6):881–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148(5):938–47.e1.CrossRefPubMedGoogle Scholar
  40. 40.
    Solem CA, Loftus Jr EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(8):707–12.CrossRefPubMedGoogle Scholar
  41. 41.
    Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21(4):824–31.CrossRefPubMedGoogle Scholar
  42. 42.
    Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59(4):829–37.CrossRefPubMedGoogle Scholar
  43. 43.
    Click B, Vargas EJ, Anderson AM, Proksell S, Koutroubakis IE, Ramos Rivers C, et al. Silent Crohn’s disease: asymptomatic patients with elevated C-reactive protein are at risk for subsequent hospitalization. Inflamm Bowel Dis. 2015;21(10):2254–61.PubMedGoogle Scholar
  44. 44.
    Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Kanel R, et al. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss inflammatory bowel disease cohort study. Eur J Gastroenterol Hepatol. 2013;25(7):790–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Koutroubakis IE, Regueiro M, Schoen RE, Ramos-Rivers C, Hashash JG, Schwartz M, et al. Multiyear patterns of serum inflammatory biomarkers and risk of colorectal neoplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2015.Google Scholar
  46. 46.
    Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(8):1342–8.e1.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18(9):1647–54.CrossRefPubMedGoogle Scholar
  48. 48.
    Jurgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9(5):421–7.e1.CrossRefPubMedGoogle Scholar
  49. 49.
    Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2011;34(8):911–22.CrossRefPubMedGoogle Scholar
  50. 50.
    Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.CrossRefPubMedGoogle Scholar
  51. 51.
    Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3.CrossRefPubMedGoogle Scholar
  52. 52.
    Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.CrossRefPubMedGoogle Scholar
  53. 53.
    van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis. 2014;20(12):2292–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80–4.e2.CrossRefPubMedGoogle Scholar
  55. 55.
    Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721–7.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(10):1708–13.CrossRefPubMedGoogle Scholar
  57. 57.
    Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014;40(6):620–8.CrossRefPubMedGoogle Scholar
  58. 58.••
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9.e3. This paper highlights the value of anti-TNF dose optimization in IBD. Optimal anti-TNF drug levels in maintenance therapy favors achieving treatment targets.CrossRefPubMedGoogle Scholar
  59. 59.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70.e5. quiz e31.CrossRefPubMedGoogle Scholar
  60. 60.
    Jung YS, Park DI, Kim ER, Kim YH, Lee CK, Lee SH, et al. Quantifying exposure to diagnostic radiation and factors associated with exposure to high levels of radiation in Korean patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(9):1852–7.PubMedGoogle Scholar
  61. 61.•
    Ordas I, Rimola J, Rodriguez S, Paredes JM, Martinez-Perez MJ, Blanc E, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology. 2014;146(2):374–82.e1. This article demonstrates the good correlation between MRE and endoscopy. It also highlights the role of MRE scores in the evaluation of treatment response.CrossRefPubMedGoogle Scholar
  62. 62.
    Caruso A, D’Inca R, Scarpa M, Manfrin P, Rudatis M, Pozza A, et al. Diffusion-weighted magnetic resonance for assessing ileal Crohn’s disease activity. Inflamm Bowel Dis. 2014;20(9):1575–83.CrossRefPubMedGoogle Scholar
  63. 63.
    Buisson A, Joubert A, Montoriol PF, Da Ines D, Hordonneau C, Pereira B, et al. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37(5):537–45.CrossRefPubMedGoogle Scholar
  64. 64.
    Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis. 2013;7(12):950–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Sauer CG, Middleton JP, McCracken C, Loewen J, Braithwaite K, Alazraki A, et al. Magnetic resonance enterography (MRE) healing and MRE remission predicts improved outcome in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015.Google Scholar
  66. 66.
    Rimola J, Ordas I. MR colonography in inflammatory bowel disease. Magn Reson Imaging Clin N Am. 2014;22(1):23–33.CrossRefPubMedGoogle Scholar
  67. 67.
    Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol. 2013;19(7):968–78.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32(2):174–8.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13–20.CrossRefPubMedGoogle Scholar
  70. 70.
    Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107(11):1684–92.CrossRefPubMedGoogle Scholar
  71. 71.
    Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–105. quiz 340–1.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12(7):543–50.CrossRefPubMedGoogle Scholar
  73. 73.
    Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, et al. Clinical course in Crohn’s disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42(5):602–10.CrossRefPubMedGoogle Scholar
  74. 74.
    Benitez JM, Louis E. Can we predict the high-risk patient? Dig Dis. 2014;32(4):328–36.CrossRefPubMedGoogle Scholar
  75. 75.
    Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep. 2009;11(6):509–17.CrossRefPubMedGoogle Scholar
  76. 76.•
    Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20(2):231–9. This article—although retrospective—highlights the importance of early re-evaluation after initiation of a treatment in IBD.CrossRefPubMedGoogle Scholar
  77. 77.•
    Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(6):978–85. This article—although retrospective—highlights the importance of early re-evaluation after initiation of a treatment in IBD.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2016

Authors and Affiliations

  1. 1.Department of Gastroenterology, University Hospitals LeuvenKULeuven–University of LeuvenLeuvenBelgium
  2. 2.Department of Gastroenterology, Imelda GI Clinical Research CentreImelda ziekenhuisBonheidenBelgium

Personalised recommendations